Danaher Corp. (DHR)
NYSE
Closed
Oct 7, 2026
Day's Range
214.4052 wk Range
160.93Overview - DHR - Danaher Corp.
Key Statistics
Valuation
Enterprise Value
174.00B
P/E (Trailing)
‪38.15‬
P/E (Forward)
‪23.01‬
PEG Ratio
‪0.63‬
Price / Sales (TTM)
‪5.99‬
Price / Book
‪2.86‬
EV / EBITDA
‪21.67‬
Profitability
Gross Margin
‪57.63%‬
Profit Margin
‪15.94%‬
Operating Margin
‪19.77%‬
Return on Assets
‪3.94%‬
Return on Equity
‪7.60%‬
Ownership
Shares Outstanding
702.90M
Float
625.86M
Short % of Shares Outstanding
‪1.33%‬
Held by Insiders
‪10.96%‬
Held by Institutions
‪84.35%‬
Price stats
Beta
‪0.80‬
50-Day Avg
‪208.79‬
200-Day Avg
‪201.60‬
Dividends
Payout Ratio
‪25.67%‬
Frequency
Quarterly
Analyst Consensus
25 analysts
Average price target
‪$ 227.96‬Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - DHR - Danaher Corp.
Peers - DHR - Danaher Corp.
Peer Comparison
Compared with companies in Diagnostics & Research listed on NYSE.
Profile Summary - DHR - Danaher Corp.
About
Danaher Corp. is a global science and technology company focused on biotechnology, life sciences, and diagnostics. The company develops and supplies mission-critical tools, consumables, instruments, software, and services used in research, bioprocessing, clinical testing, and laboratory workflows. Its current business…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
